Fig. 2

Effects of GANT61 and ADR on the cell viability of primary cells. (A-B) The relative cell viability after treatment of ADR (1.6µM), GANT61 (20µM), or both for 24 H in primary cells from healthy donors (A) or de novo patients with AML (B). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns, not significant